Science

Jan 30, 2025, 08:44

Final analysis of the PRECIOUS phase 3 trial

Paolo Tarantino, Clinical Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared an article by Yutaka Yamamoto, et al. on X:

“Final analysis of the PRECIOUS phase 3 trial out in Journal of Clinical Oncology.

Despite yielding only a small PFS advantage, pertuzumab rechallenge in HER2+ MBC led to a relevant OS benefit (Δ 10 mo). Could become actionable if T-DXd/pertuzumab make it to the first line.”

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.

Authors: Yutaka Yamamoto, et al.

Final analysis of the PRECIOUS phase 3 trial

cancer Dana-Farber Cancer Institute fight against cancer Global fight against cancer Harvard Medical School Journal of Clinical Oncology metastatic breast cancer OncoDaily Oncology Paolo Tarantino pertuzumab Yutaka Yamamoto

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC